Quince Therapeutics, a biotechnology company dedicated to acquiring, developing, and bringing innovative therapeutics to market, has recently announced its agreement to acquire EryDel SpA, a late-stage biotech company. This acquisition will involve an upfront exchange of stocks and potential cash payments based on future milestones. EryDel has made significant advancements in the field with their autologous intracellular drug encapsulation (AIDE) technology and their lead asset, EryDex, currently in Phase 3 clinical trials for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurological disease that lacks approved treatments. The transaction is expected to be finalized in the third quarter of 2023.
By acquiring EryDel, Quince will have the means to fully finance the development of EryDex through Phase 3 clinical trials under a special protocol assessment (SPA). Additionally, this acquisition opens up the possibility of submitting EryDex for new drug application (NDA). What sets EryDex apart is its utilization of AIDE technology, which allows for controlled release of steroids over several weeks without causing long-term toxicity associated with chronic